Verona Pharma VRNA

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Verona Pharma (VRNA) Business Model and Operations Summary
    Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

    Key Insights

    Verona Pharma (VRNA) Core Market Data and Business Metrics
    • Latest Closing Price

      $105.91
    • Market Cap

      $5.54 Billion
    • Average Daily Volume

      1,378,874 Shares
    • 52-Week Range

      $11.39-$70.40
    • Total Outstanding Shares

      86.50 Million Shares
    • CEO

      Dr. David S. Zaccardelli Pharm.D.
    • Total Employees

      209
    • Current Dividend

      No dividend
    • IPO Date

      April 27, 2017
    • SIC Description

      Pharmaceutical Preparations
    • Headquarters

      3 More London Riverside, London, X0, SE1 2RE

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Balance Sheet

    July 1, 2024 to June 30, 2025

    Historical Stock Splits

    Historical Dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about VRNA from trusted financial sources

    Related Companies

    Publicly traded companies similar to Verona Pharma (VRNA)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.